Celldex Therapeutics Profile, SWOT Analysis and Company Tech Intelligence Report 2018

Report Name: Celldex Therapeutics  Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

Celldex Therapeutics  Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

Celldex Therapeutics   – Business Description:

Celldex Therapeutics  is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The company operates in the US.

Celldex operates in one business segment: the development, manufacturing and commercialization of novel therapeutics for human health care.

The company had out-licensed its oral rotavirus strain to GlaxoSmithKline (GSK) for royalties on sales of the vaccine. GSK marketed Rotavirus vaccine as Rotarix. However, Celldex’s agreement with GSK terminated in 2012 upon the anticipated expiration of the last relevant patent right covered by the GSK agreement. Hence, Celldex does not expect additional royalty revenue or royalty expense related to Rotarix. The retained interests in Rotarix net royalties are recorded as product royalty revenue.

Celldex’s primary focus is on oncology. The company’s lead drug candidates include: rindopepimut (also referred to as Rintega and CDX-110), is a therapeutic vaccine in clinical studies for the treatment of glioblastoma. rindopepimut completed the enrolment in ACT IV, a Phase 3 study in front-line glioblastoma; Glembatumumab vedotin (also referred to as CDX-011) an antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma; In addition, the company has a number of earlier stage candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an antibody-targeted technology (APC) targeting technology program for cancer indications. CDX-014 is being investigated in preclinical studies as an immunotherapy treatment for renal and ovarian cancer.

Celldex develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical partners, collaborators and agreements, including Rockefeller University, Duke University Brain Tumor Cancer Center, Medarex (a subsidiary of Bristol-Myers Squibb) and others. The company has a manufacturing facility in Fall River, Massachusetts, which produces clinical materials for the company’s current and planned Phase 1 and Phase 2 clinical trials.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Purchase Now

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
+1 888 709 8757

Be the first to comment

Leave a Reply